{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:12:51Z","timestamp":1791947571884,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.rpth.2023.102239","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T11:23:25Z","timestamp":1697887405000},"page":"102239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"Cedric","family":"Hermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samya","family":"Obaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Beckermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Lehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Catalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"d\u2019Oiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2023.102239_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.102239_bib2","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102239_bib3","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2023.102239_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2023.102239_bib5","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/hae.14403","article-title":"Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States","volume":"27","author":"Miller","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.102239_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14535","article-title":"Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues","volume":"28","author":"Weyand","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.102239_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41431-020-00742-4","article-title":"X\u00a0Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers","volume":"29","author":"Garagiola","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.rpth.2023.102239_bib10","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/hae.12364","article-title":"Severe and moderate haemophilia A and B in US females","volume":"20","author":"Di Michele","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.102239_bib11","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/jth.15397","article-title":"A\u00a0new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH","volume":"19","author":"van Galen","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102239_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hae.14094","article-title":"Women and girls with haemophilia: lessons learned","volume":"27","author":"d'Oiron","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.102239_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102239_bib14","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.102239_bib15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients with hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102239_bib16","doi-asserted-by":"crossref","first-page":"E295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2023.102239_bib17","article-title":"Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res Prac Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102239_bib18","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/bloodadvances.2020002364","article-title":"First report of emicizumab use in a female patient with severe hemophilia A","volume":"4","author":"Verstraete","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2023.102239_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures","volume":"26","author":"McCary","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.102239_bib20","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2022-157754","article-title":"Emicizumab and females with hemophilia A: case series from ATHN 7","volume":"140","author":"Recht","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.102239_bib21","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in moderate and mild hemophilia A: results of the phase 3 HAVEN 6 study","volume":"10","author":"Negrier","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2023.102239_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/1471-0528.13273","article-title":"The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding","volume":"122","author":"Matteson","year":"2015","journal-title":"Br J Obst Gynaecol"},{"key":"10.1016\/j.rpth.2023.102239_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"Br J Obst Gynaecol"},{"key":"10.1016\/j.rpth.2023.102239_bib24","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1182\/blood.V122.21.4772.4772","article-title":"Establishment of a reference range for the Pbac-Score","volume":"122","author":"Halimeh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.102239_bib25","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1111\/hae.14421","article-title":"Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Parnes","year":"2021","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923004995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923004995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:28:13Z","timestamp":1762864093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037923004995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2475037923004995"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2023.102239","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2023.102239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102239"}}